57 results about "Oncocyte" patented technology

This invention provides the capture antibody and the detection antibody to detect the aspergillus, the two antibody is the single clone antibody of the cross oncocyte CCTCC NO.C200731 and CCTCC NO.C200730, they can unites the glucoprotein whose molecular weight is 25-100kDa in the cell wall of the aspergillus, the reaction with the Penicillium marneffei, white oidiomycosis, smoothness oidiomycosis, tropic oidiomycosis, close smoothness oidiomycosis, Candida krusei are all negative. The antibody in this invention can make into the immunity reagent to detect the aspergillus in common use.

The invention relates to a transcription mesosome Med23 subunit serving as a target for preventing or treating cancer. Specifically, the deletion of the transcription mesosome Med23 can influence the growth and tumor forming capacity of the ras-active lung cancer cell strain and obviously reduce the conversion efficiency from oncogene ras into MEF cell. Meanwhile, the expression quantity of Med23 is obviously increased in the conversion process; and the result of chip analysis shows that the deletion of Med23 influences the expression of the ras feature gene, and the Med23 acts with Elk1 to together regulate the cell cycle/cell proliferation related gene. The Med23 is remarkably highly expressed in the ras-active lung cancer cell strain and a clinical sample of lung cancer, and the expression quantity is remarkably related to prognosis; and the deletion of Med23 also can reduce the tolerance of the cancer cells to the chemotherapeutic drugs. Therefore, the Med23 is a potential cancer treatment target.

The invention aims to provide an application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma. Experiments show that the chlorogenic acid can activate CD4 T-lymphocytes and CD8 T-lymphocytes, and prevent and treat primary cutaneous T-cell lymphoma by taking the CD4 T-lymphocytes and the CD8 T-lymphocytes as targets. According to the invention, the chlorogenic acid is adopted for promoting the proliferation of T-lymphocytes of a body and activating the T-lymphocytes so as to achieve the purpose of treating primary cutaneous T-cell lymphoma. Meanwhile, the chlorogenic acid also can inhibit the proliferation of primary cutaneous T-cell lymphoma cells, and the inhibition effect of the chlorogenic acid is similar to the inhibition effect of interferon.

The invention relates to a preparation method of an organic hybrid trinuclear platinum complex possessing a Y type structure synthesized by supermolecules self-assembly as well as treatment for gastric adenocarcinoma cells. The MTT experiment data shows that the compound can cross a drug resistance mechanism of cisplatin, and can specifically target to the gastric adenocarcinoma cells. A platinum ligand Pt(NH3)2Cl(NO3)] in which the chloride ion is replaced by nitrate and a bridge ligand (2,4,6-tri(pyridin-4-yl)-1,3,5-triazine) are subjected to self-assembly, thereby the novel and latent medicine for treating gastric adenocarcinoma with excellent anticancer activity and tumor targeting is obtained. Because the complex enables specific recognition of the gastric adenocarcinoma cells, and can induce the G-rich sequence of the oncogene to form a G-quadruplex structure, the activity of telomerase can be inhibited, thereby the complex possesses high gastric adenocarcinoma resistance activity. The preparation method has the advantages of simple process and low cost, can be completed in a general chemical laboratory, and the production process is environmentally-friendly. The trinuclear platinum complex possessing Y type structure can be taken as the novel and latent gastric adenocarcinoma resistance medicine.

The invention discloses a preparation method of an alpha-glucan antigen and a specificity monoclonal antibody. The preparation method of the antigen comprises the following steps: mixing alpha-glucan and protein; dissolving with water; regulating the pH of solution to 5-8; carrying out freeze drying, and grinding into powder; putting the powder in the environment with constant temperature of 50-60DEG C and relative humidity of 60-90%; reacting for at least three days to obtain the alpha-glucan antigen. The preparation method of the antibody comprises the following steps: mixing the prepared antigen with an adjuvant, emulsifying the mixture, and injecting the emulsified mixture into animal bodies; blending the splenocyte and oncocyte of the animal body with the high serum valence to obtain a hybridoma cell capable of secreting the antibody; and producing the antibody by the hybridoma cell or with an ascites method. The antibody prepared by the method has high immunogenicity, and can be used for effectively inducing to generate immune response to obtain the antibody with the excellent property. The antibody obtained by the method provided by the invention can be subjected to specificity reaction with the alpha-glucan to generate macroscopic precipitates, and the antibody has high valence and can be used for the quantitative analysis on the alpha-glucan.

The invention discloses a novel peptide deformylase inhibitor containing spiro-three-membered ring and spiro-five-membered ring types. The novel peptide deformylase inhibitor containing the spiro-three-membered ring and spiro-five-membered ring types has antibacterial activity and anti-tumor activity. The peptide deformylase inhibitor containing the spiro-three-membered ring and spiro-five-membered ring types can serve as a novel antibacterial agent, by inhibiting the activity of peptide deformylase needed in synthesis of bacterium proteins, the novel peptide deformylase inhibitor is effective on multiple antibiotic resistant Gram-positive bacterium strains, the synthesis process of proteins of human bodies is not affected, and accordingly bacteria are killed selectively. The peptide deformylase inhibitor containing the spiro-three-membered ring and spiro-five-membered ring types can further serve as a novel anti-cancer drug; by inhibiting peptide deformylase in mitochondria of cancer cells, energy balance of the cells can be affected, accordingly mitochondrial membranes are depolarized, ATP is used up, and cell apoptosis is promoted; and the novel peptide deformylase inhibitor has good inhibiting activity to multiple cancer cell bacterial strains such as colorectal cancer cell bacterial strains, lung cancer cell bacterial strains, gastric cancer cell bacterial strains and liver cancer cell bacterial strains at the low concentration.

The invention discloses a polypeptide chip of monoclonal antibody group screening with different antigen epitopes, which comprises the following steps: 1. synthesizing polypeptide according to the screened antigen of monoclonal antibody group; preparing polypeptide chip; 2. mixing the cell suspension of immune mouse spleen with the antigen and myeloid oncocyte at certain proportion; fusing two cell through fluxing agent to generate hybrid oncocyte; 3. collecting the hybrid oncocyte; cultivating for 7-8 days; making suspending liquid; 4. adapting polypeptide chip of different antigen epitopes to screen and identify the suspending liquid of hybrid oncocyte; 5. establishing a group of monoclonal antibody cell plant of different antigen epitopes with the positive clone screened and identified by polypeptide chip; 6. generating monoclonal antibody group of different antigen epitopes through cultivation enlargement and purity segregation.

It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising:

• step (a) of selectively reducing KLRG1-positive immunocytes in the peripheral blood of a living individual with epithelial cancer ex vivo, which is positive for a cancer-specific membrane antigen expressed in epithelial cancer cells and positive for a KLRG1 ligand; and
• step (b) of administering, to the living individual, a therapeutic agent for cancer comprising an antibody reacting with the cancer-specific membrane antigen expressed in epithelial cancer cells and having antibody-dependent cell cytotoxicity.

The invention provides an application of Walker-256 cell strains in establishing a bone tumor pain model, in particular to an application of the Walker-256 cell strains in establishing a large rat bone tumor pain model. The application of the Walker-256 cell strains of the invention has successfully established the large rat bone tumor pain model. The establishment of the tumor pain model provides a useful tool for research of topics relating to bone tumor pain and particularly filtration of tumor pain resistant traditional Chinese medicines and compounds of the tumor pain resistant traditional Chinese medicines; moreover, the cell strains are derived from large rat primary breast carcinoma tissues, thereby the bone tumor pain model established by application of oncocyte can be regarded as a breast carcinoma transition model, and the invention has significant scientific research value and application prospect.

The invention relates to an animal influenza target drug and relative production. Wherein, it uses single colon antibody to select the cross oncocyte seed which can resist animal influenza virus and inflammatory facto, and it can extract different cross oncocytes, via RT-PCT to obtain heavy chain variable area and light chain variable area genes with single antibody; and via SOE-PCT, to connect the VH, VL genes with one short peptide with 15 amino acid, to build the single chain antibody gene of single chain antibody gene, or single chain dual special antibody gene, and inflammatory facto, and connect the single chain antibody gene or single chain dual special antibody gene, via enzyme cutting to connect the single chain antibody gene or bacillus pyocyaneus ectotoxin PE40 gene of inflammatory facto, to build original core represent carrier, transfer Ecoli.BL21 projective virus, then via ferment, extraction, and purification, to obtain target antagonist.

The invention discloses a LRP16 single cloned antibody hybrid tumor cell line CGMCC 1992 and the application of the cell line, and pertains to the technical field of medicine biology. The advantages with the invention are: 1) the chromosome is steady, and the cell line will secrete IgG1 antibody; 2) the cell line can be cultured in a no-serum culturing system; 3) the titer of the secreted antibody is high, the upper serum directly cultured can be up to 1:200,000; 4) abdominal dropsy of rat can be up to 1 mg/ml; the titer can be up to 1: 3,600,000, and can be purified by protein G; 5) the secreted antibody can be used for immunity combination (1:1000) and immunity mark (western blot) test (1:3000).

The invention discloses an application of an oncogenic kinase marker for liver cancer diagnosis and treatment, and discloses an application of oncogenic kinase STK39 in liver cancer diagnosis and treatment. The expression difference of the STK39 in normal liver tissues and liver cancer tissues is found for the first time, the expression quantity of the STK39 in the liver cancer tissues is obviously higher than that in the normal tissues, and a patient with high expression of the STK39 has poor prognosis, so that the STK39 is prompted to be closely related to occurrence, development and prognosis of the liver cancer. Knockdown, knockout and inhibition of STK39 can obviously inhibit the growth and invasion of hepatoma carcinoma cells, and it is indicated that STK39 can be used as a new target for diagnosis and treatment of hepatoma carcinoma. A kit and the technology for checking STK39 expression can be applied to liver cancer diagnosis and prognosis prediction, and treatment strategiessuch as antibodies or small molecule inhibitors of targeted oncokinase STK39 are expected to be applied to liver cancer treatment.

The invention relates to pediococcus acidilactici with an anti-cervical cancer effect. The name of the pediococcus acidilactici is HAO2018; the classification name is Pediococcus acidilactici; the preservation number is CGMCC No.16658, the preservation date is October 30, No. 3, Yard 1, West Beichen Road, Chaoyang District, Beijing, and the preservation unit is China General Microbiological Culture Collection Center. The pediococcus acidilactici can inhibit proliferation of cervical cancer HeLa cells, cause apoptosis of the HeLa cells, inhibit expression of human papilloma virus HPVE6 and E7 proteins and inhibit acetylation modification of histone in Hela cells. The Pediococcus acidilactici has good cervical cancer cell inhibition performance, is used for preparing a cervical cancer inhibition fermentation product and has a very wide application prospect.

The invention discloses a medicine for treating lung cancer. The medicine is composed of NG25 and trametinib at a mass ratio of 4 to 1; and the lung cancer is a lung cancer in which the function of CLU genes is absent or down-regulated. Further, the lung cancer is a lung cancer in which the function of the CLU genes is absent or down-regulated and is driven by KRASG 12D oncogenes. In vitro experiments show that CLU knock-down lung cancer cells are more sensitive to NG25, compared with controls, the NG25 can significantly inhibit the growth of the lung cancer cells, and while after the cells are treated by combining with the Trametinib, it is found that the inhibition on the lung cancer cells is even more significant. Similarly, in animal models, a TAK1 inhibitor NG25 can inhibit the growthof CLU knock-down cell transplantation tumors and CLU knock-out orthotopic lung cancer, the treatment combined with the Trametinib can significantly shrink the tumor, and the purpose of treating thetype of the lung cancer is achieved.

The present invention describes new compounds that are useful for image-guided surgery and photodynamic therapy. In particular the compounds may be targeted to the nucleus or the mitochondria after compounds were delivered to diseased tissues such as cancer using a ligand that target receptor that express on the diseased tissue and followed by receptor mediated endocytosis and provide effective activity against cancer cells as well as other disorders. Methods and compositions for use of the same are described.

The invention relates to a method for inhibiting the proliferation of gastric cancer and drugs thereof. The method comprises the steps that through the reduction of the copy number of gastric cancer cell mitochondria mtDNA and the expression of DNA polymerase gamma, oxidative stress is enhanced and further metabolism disorders of cell energy are triggered in order to inhibit the proliferation of gastric cancer cells. The technical scheme has the technical effects of being effective in inhibiting the proliferation of gastric cancer.

The present invention provides novel mito-pyridinium compounds, prodrugs and the uses thereof for the treatment of cancer, particularly drug resistant cancer.

The present invention discloses one kind of medicine for treating women' s tumors and malignant tumors and its preparation process. The medicine is prepared with 15 kinds of Chinese medicinal materials, including motherwort, phellodendron bark, aweto, glossy ganoderma, saffron, etc in certain weight proportion. The medicine has the functions of promoting blood circulation to disperse blood clots,clearing away heat and toxic material, raising immunity, etc.